Business Description
Pro Medicus Ltd
ISIN : AU000000PME8
Share Class Description:
ASX:PME: Ordinary SharesTotal Employee Number:
75Description
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 87.82 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 126.6 | |||||
Beneish M-Score | -2.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 31.6 | |||||
3-Year EBITDA Growth Rate | 33.2 | |||||
3-Year EPS without NRI Growth Rate | 37.3 | |||||
3-Year FCF Growth Rate | 25.4 | |||||
3-Year Book Growth Rate | 36.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 26.99 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 23.92 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.41 | |||||
9-Day RSI | 59.29 | |||||
14-Day RSI | 54.27 | |||||
3-1 Month Momentum % | 53.84 | |||||
6-1 Month Momentum % | 27.11 | |||||
12-1 Month Momentum % | -33.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.22 | |||||
Quick Ratio | 6.22 | |||||
Cash Ratio | 4.55 | |||||
Days Inventory | 96.27 | |||||
Days Sales Outstanding | 97.72 | |||||
Days Payable | 11064.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.36 | |||||
Dividend Payout Ratio | 0.25 | |||||
3-Year Dividend Growth Rate | 37.7 | |||||
Forward Dividend Yield % | 0.37 | |||||
5-Year Yield-on-Cost % | 1.77 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 0.45 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.87 | |||||
Operating Margin % | 74.16 | |||||
Net Margin % | 97.59 | |||||
EBITDA Margin % | 77.38 | |||||
FCF Margin % | 50.08 | |||||
OCF Margin % | 53.16 | |||||
ROE % | 81.1 | |||||
ROA % | 60.34 | |||||
ROIC % | 73.76 | |||||
3-Year ROIIC % | 121.31 | |||||
ROC (Joel Greenblatt) % | 567.73 | |||||
ROCE % | 51.42 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 80.31 | |||||
Forward PE Ratio | 97.69 | |||||
PE Ratio without NRI | 80.31 | |||||
Shiller PE Ratio | 380.5 | |||||
Price-to-Owner-Earnings | 144.63 | |||||
PEG Ratio | 2.34 | |||||
PS Ratio | 78.4 | |||||
PB Ratio | 48.41 | |||||
Price-to-Tangible-Book | 51.32 | |||||
Price-to-Free-Cash-Flow | 156.5 | |||||
Price-to-Operating-Cash-Flow | 147.55 | |||||
EV-to-EBIT | 104.27 | |||||
EV-to-Forward-EBIT | 119.1 | |||||
EV-to-EBITDA | 99.95 | |||||
EV-to-Forward-EBITDA | 111.11 | |||||
EV-to-Revenue | 77.34 | |||||
EV-to-Forward-Revenue | 51.65 | |||||
EV-to-FCF | 136.81 | |||||
Price-to-GF-Value | 0.71 | |||||
Price-to-Projected-FCF | 19.45 | |||||
Price-to-DCF (Earnings Based) | 2.57 | |||||
Price-to-DCF (FCF Based) | 5.01 | |||||
Price-to-Median-PS-Value | 1.49 | |||||
Price-to-Peter-Lynch-Fair-Value | 6.54 | |||||
Price-to-Graham-Number | 13.53 | |||||
| Price-to-Net-Current-Asset-Value | 116.97 | |||||
| Price-to-Net-Cash | 240.19 | |||||
Earnings Yield (Greenblatt) % | 0.94 | |||||
FCF Yield % | 0.64 | |||||
Forward Rate of Return (Yacktman) % | 20.34 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pro Medicus Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 240.492 | ||
| EPS (TTM) (A$) | 2.243 | ||
| Beta | 1.3056 | ||
| 3-Year Sharpe Ratio | 0.7 | ||
| 3-Year Sortino Ratio | 1.23 | ||
| Volatility % | 75.14 | ||
| 14-Day RSI | 54.27 | ||
| 14-Day ATR (A$) | 7.607311 | ||
| 20-Day SMA (A$) | 178.2915 | ||
| 12-1 Month Momentum % | -33.72 | ||
| 52-Week Range (A$) | 107.75 - 324.49 | ||
| Shares Outstanding (Mil) | 104.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pro Medicus Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pro Medicus Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-24 10:00 | In 111 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-14 11:00 | In 9 days | ||
| Annual report for 2026 | 2026-08-14 | In 8 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-14 | In 8 days | ||
| AUD 0.320000 Cash Dividend | 2026-02-26 | 116.23 (+5.75%) | ||
| Second quarter earnings results for 2026 | 2026-02-12 | 169.47 (+2.71%) | ||
| General meeting for 2025 | 2025-11-24 10:00 | 251.32 (+2.14%) | ||
| AUD 0.300000 Cash Dividend | 2025-09-03 | 294.67 (-1.74%) | ||
| Fourth quarter earnings conference call for 2025 | 2025-08-14 11:00 | 297.15 (-2.37%) | ||
| Annual report for 2025 | 2025-08-14 | 297.15 (-2.37%) |
Show
Entries
Pro Medicus Ltd Frequently Asked Questions
What is Pro Medicus Ltd(ASX:PME)'s stock price today?
The current price of ASX:PME is A$180.14. The 52 week high of ASX:PME is A$324.49 and 52 week low is A$107.75.
When is next earnings date of Pro Medicus Ltd(ASX:PME)?
The next earnings date of Pro Medicus Ltd(ASX:PME) is 2026-08-14 Est..
Does Pro Medicus Ltd(ASX:PME) pay dividends? If so, how much?
The Dividend Yield %  of Pro Medicus Ltd(ASX:PME) is 0.36% (As of Today), Highest Dividend Payout Ratio of Pro Medicus Ltd(ASX:PME) was 0.48. The lowest was 0.25. And the median was 0.43. The  Forward Dividend Yield % of Pro Medicus Ltd(ASX:PME) is 0.37%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Visage Highlights One Platform AI-Optimized at SIIM26 | 2026-06-08 | ||
| Visage Elevates AI Optimized Enterprise Imaging at HIMSS26 | 2026-03-10 | ||
| Visage Propels AI Optimized Enterprise Imaging at RSNA 2025 | 2025-11-19 | ||
| Visage Achieves Authority to Operate (ATO) from the U.S. Department of Veterans Affairs | 2025-09-04 | ||
| Visage Transforms Imaging to the Cloud at RSNA 2024 | 2024-11-12 | ||
| Visage Leads with CloudPACS at SIIM 2024 | 2024-06-25 | ||
| Visage Soars with CloudPACS at RSNA 2023 | 2023-11-14 | ||
| Visage 7 Named Best in KLAS 2023 | 2023-02-08 | ||
| Visage Announces Support of Amazon HealthLake Imaging | 2022-11-27 | ||
| Visage Leads with CloudPACS at RSNA 2022 | 2022-11-14 |
Articles on Pro Medicus Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers